EU filing for Clovis’ Rubraca in ovarian cancer maintenance setting
Clovis Oncology is seeking to expand use of its PARP inhibitor Rubraca in Europe to include maintenance treatment of certain adults with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Read More





